Proceedings of the 2023 Santa Fe Bone Symposium: Progress and Controversies in the Management of Patients with Skeletal Diseases

J Clin Densitom. 2023 Oct-Dec;26(4):101432. doi: 10.1016/j.jocd.2023.101432. Epub 2023 Oct 14.


The Santa Fe Bone Symposium (SFBS) held its 23rd annual event on August 5-6, 2023, in Santa Fe, New Mexico, USA. Attendees participated in-person and remotely, representing many states and countries. The program included plenary presentations, panel discussions, satellite symposia, a Project ECHO workshop, and a session on healthcare policy and reimbursement for fracture liaison programs. A broad range of topics were addressed, including transitions of osteoporosis treatments over a lifetime; controversies in vitamin D; update on Official Positions of the International Society for Clinical Densitometry; spine surgery and bone health; clinical applications of bone turnover markers; basic bone biology for clinicians; premenopausal-, pregnancy-, and lactation-associated osteoporosis; cancer treatment induced bone loss in patients with breast cancer and prostate cancer; genetic testing for skeletal diseases; and an update on nutrition and bone health. There were also sessions on rare bone diseases, including managing patients with hypophosphatasia; treatment of X-linked hypophosphatemia; and assessment and treatment of patients with hypoparathyroidism. There were oral presentations of abstracts by endocrinology fellows selected from those who participated in the Santa Fe Fellows Workshop on Metabolic Bone Diseases, held the 2 days prior to the SFBS. These proceedings of the 2023 SFBS present the clinical highlights and insights generated from many formal and informal discussions in Santa Fe.

Keywords: ECHO; ISCD; Nutrition; Osteoporosis; Vitamin D.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Absorptiometry, Photon
  • Bone Density
  • Bone Diseases, Metabolic* / etiology
  • Bone Diseases, Metabolic* / therapy
  • Female
  • Fractures, Bone* / therapy
  • Humans
  • Male
  • Osteoporosis* / drug therapy


  • N-succinimidyl 8-((4'-fluorobenzyl)amino)suberate